Chemokine Binding to Tenascin-C Influences Chemokine-Induced Immune Cell Migration

Tenascin-C (TNC) is a complex glycoprotein of the extracellular matrix (ECM) involved in a plethora of (patho-)physiological processes, such as oncogenesis and inflammation. Since chemokines play an essential role in both disease processes, we have investigated here the binding of TNC to some of the key chemokines, namely CCL2, CCL26, CXCL8, CXCL10, and CXCL12. Thereby, a differential chemokine-TNC binding pattern was observed, with CCL26 exhibiting the highest and CCL2 the lowest affinity for TNC. Heparan sulfate (HS), another member of the ECM, proved to be a similarly high-affinity ligand of TNC, with a Kd value of 730 nM. Chemokines use glycosa-minoglycans such as HS as co-receptors to induce immune cell migration. Therefore, we assumed an influence of TNC on immune cell chemotaxis due to co-localization within the ECM. CCL26- and CCL2-induced mobilization experiments of eosinophils and monocytes, respectively, were thus performed in the presence and the absence of TNC. Pre-incubation of the immune cells with TNC resulted in a 3.5-fold increase of CCL26-induced eosinophil chemotaxis, whereas a 1.3-fold de-crease in chemotaxis was observed when monocytes were pre-incubated with CCL2. As both chemokines have similar HS binding but different TNC binding affinities, we speculate that TNC acts as an attenuator in monocyte and as an amplifier in eosinophil mobilization by impeding CCL2 from binding to HS on the one hand, and by reinforcing CCL26 to bind to HS on the other hand.

[1]  M. Mörgelin,et al.  Investigating Chemokine-Matrix Networks in Breast Cancer: Tenascin-C Sets the Tone for CCL2 , 2023, International journal of molecular sciences.

[2]  C. Donovan,et al.  Tenascin C in Lung Diseases , 2023, Biology.

[3]  R. Tucker,et al.  Advances on the roles of tenascin-C in cancer , 2022, Journal of cell science.

[4]  A. Kungl,et al.  The Role of Heparan Sulfate in CCL26-Induced Eosinophil Chemotaxis , 2022, International journal of molecular sciences.

[5]  S. Bhattacharyya,et al.  Tenascin-C in fibrosis in multiple organs: Translational implications. , 2022, Seminars in cell & developmental biology.

[6]  K. Midwood,et al.  Editorial: Tenascins – Key Players in Tissue Homeostasis and Defense , 2022, Frontiers in Immunology.

[7]  O. Gualillo,et al.  Chemokines and chemokine receptors in inflammatory bowel disease: recent findings and future perspectives. , 2021, Drug discovery today.

[8]  R. Sachidanandam,et al.  High endogenous CCL2 expression promotes the aggressive phenotype of human inflammatory breast cancer , 2021, Nature Communications.

[9]  A. Kungl,et al.  Isolation and Characterization of Heparan Sulfate from Human Lung Tissues , 2021, Molecules.

[10]  K. Imanaka-Yoshida Tenascin-C in Heart Diseases—The Role of Inflammation , 2021, International journal of molecular sciences.

[11]  N. Paul,et al.  Tenascin‐C immobilizes infiltrating T lymphocytes through CXCL12 promoting breast cancer progression , 2021, EMBO molecular medicine.

[12]  A. Kungl,et al.  Glycosaminoglycans located on neutrophils and monocytes impact on CXCL8- and CCL2-induced cell migration. , 2021, Cytokine.

[13]  C. Deligne,et al.  Macrophages and Extracellular Matrix in Breast Cancer: Partners in Crime or Protective Allies? , 2021, Frontiers in Oncology.

[14]  C. Weber,et al.  Inflammatory Chemokines in Atherosclerosis , 2021, Cells.

[15]  A. Sudo,et al.  Tenascin-C in Osteoarthritis and Rheumatoid Arthritis , 2020, Frontiers in Immunology.

[16]  Katarzyna Rolle,et al.  Down-regulation of tenascin-C inhibits breast cancer cells development by cell growth, migration, and adhesion impairment , 2020, PloS one.

[17]  M. Congreve,et al.  Impact of GPCR Structures on Drug Discovery , 2020, Cell.

[18]  K. Midwood,et al.  More Than Just Attractive: How CCL2 Influences Myeloid Cell Behavior Beyond Chemotaxis , 2019, Front. Immunol..

[19]  E. Krieger,et al.  PEGylation of a glycosaminoglycan-binding, dominant-negative CXCL8 mutant retains bioactivity in vitro and in vivo. , 2019, Cytokine.

[20]  Jihua Liu,et al.  The effect of heparan sulfate on promoting amyloid fibril formation by β-casein and their binding research with multi-spectroscopic approaches. , 2019, Journal of photochemistry and photobiology. B, Biology.

[21]  H. Kettenmann,et al.  Tenascin C regulates multiple microglial functions involving TLR4 signaling and HDAC1 , 2019, Brain, Behavior, and Immunity.

[22]  M. Najafi,et al.  Extracellular matrix (ECM) stiffness and degradation as cancer drivers , 2018, Journal of cellular biochemistry.

[23]  Olivier Stettler,et al.  The role of heparan sulfates in protein aggregation and their potential impact on neurodegeneration , 2018, FEBS letters.

[24]  W. Gong,et al.  Chemokines in homeostasis and diseases , 2018, Cellular & Molecular Immunology.

[25]  M. Chiquet,et al.  Tenascin-C at a glance , 2016, Journal of Cell Science.

[26]  A. Kungl,et al.  Exploring the glycosaminoglycan–protein interaction network by glycan‐mediated pull‐down proteomics , 2016, Electrophoresis.

[27]  T. Oskarsson,et al.  The extracellular matrix in breast cancer. , 2016, Advanced drug delivery reviews.

[28]  A. Theocharis,et al.  Extracellular matrix structure. , 2016, Advanced drug delivery reviews.

[29]  Aid Atlić,et al.  Designing a mutant CCL2-HSA chimera with high glycosaminoglycan-binding affinity and selectivity. , 2015, Protein engineering, design & selection : PEDS.

[30]  T. Oskarsson,et al.  Tenascin C in metastasis: A view from the invasive front , 2015, Cell adhesion & migration.

[31]  M. Chiquet,et al.  Transcriptional regulation of tenascin genes , 2015, Cell adhesion & migration.

[32]  Toshimichi Yoshida,et al.  Tenascin-C and integrins in cancer , 2015, Cell adhesion & migration.

[33]  K. Midwood,et al.  Tenascin-C: Form versus function , 2014, Cell adhesion & migration.

[34]  M. Chiquet,et al.  Tenascins in stem cell niches. , 2014, Matrix biology : journal of the International Society for Matrix Biology.

[35]  A. Kungl,et al.  A Combinatorial Approach to Biophysically Characterise Chemokine-Glycan Binding Affinities for Drug Development , 2014, Molecules.

[36]  S. Carr,et al.  Extracellular matrix signatures of human primary metastatic colon cancers and their metastases to liver , 2014, BMC Cancer.

[37]  J. Esko,et al.  Demystifying heparan sulfate-protein interactions. , 2014, Annual review of biochemistry.

[38]  E. Karnaukhova,et al.  Oversulfated Chondroitin Sulfate Binds to Chemokines and Inhibits Stromal Cell-Derived Factor-1 Mediated Signaling in Activated T Cells , 2014, PloS one.

[39]  M. Teixeira,et al.  Designing CXCL8-based decoy proteins with strong anti-inflammatory activity in vivo , 2013, Bioscience reports.

[40]  T. Williams,et al.  Editorial: Are all eotaxins created equal? , 2013, Journal of leukocyte biology.

[41]  M. Trinker,et al.  Structure‐based design of decoy chemokines as a way to explore the pharmacological potential of glycosaminoglycans , 2012, British journal of pharmacology.

[42]  A. Zlotnik,et al.  The chemokine superfamily revisited. , 2012, Immunity.

[43]  Steven A. Carr,et al.  The Matrisome: In Silico Definition and In Vivo Characterization by Proteomics of Normal and Tumor Extracellular Matrices , 2011, Molecular & Cellular Proteomics.

[44]  J. Prestegard,et al.  Oligomeric structure of the chemokine CCL5/RANTES from NMR, MS, and SAXS data. , 2011, Structure.

[45]  B. Langlois,et al.  Advances in tenascin-C biology , 2011, Cellular and Molecular Life Sciences.

[46]  Jinghang Zhang,et al.  CCL2 recruits inflammatory monocytes to facilitate breast tumor metastasis , 2011, Nature.

[47]  Valerie M. Weaver,et al.  The extracellular matrix at a glance , 2010, Journal of Cell Science.

[48]  M. Bianchi,et al.  Requirement of HMGB1 for stromal cell–derived factor–1/CXCL12–dependent migration of macrophages and dendritic cells , 2009, Journal of leukocyte biology.

[49]  Risto Penttinen,et al.  Extracellular Matrix Molecules: Potential Targets in Pharmacotherapy , 2009, Pharmacological Reviews.

[50]  G. Schultz,et al.  Interactions between extracellular matrix and growth factors in wound healing , 2009, Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society.

[51]  Ying-Yu Chen,et al.  Monocyte Migration and LFA-1-Mediated Attachment to Brain Microvascular Endothelia Is Regulated by SDF-1α through Lyn Kinase1 , 2008, The Journal of Immunology.

[52]  T. Curtis,et al.  Advanced glycation of fibronectin impairs vascular repair by endothelial progenitor cells: implications for vasodegeneration in diabetic retinopathy. , 2008, Investigative ophthalmology & visual science.

[53]  M. Ratajczak,et al.  Migration of Bone Marrow and Cord Blood Mesenchymal Stem Cells In Vitro Is Regulated by Stromal‐Derived Factor‐1‐CXCR4 and Hepatocyte Growth Factor‐c‐met Axes and Involves Matrix Metalloproteinases , 2006, Stem cells.

[54]  M. Jinnin,et al.  Platelet derived growth factor induced tenascin‐C transcription is phosphoinositide 3‐kinase/Akt‐dependent and mediated by Ets family transcription factors , 2006, Journal of cellular physiology.

[55]  N. C. Price,et al.  How to study proteins by circular dichroism. , 2005, Biochimica et biophysica acta.

[56]  T. Handel,et al.  Regulation of protein function by glycosaminoglycans--as exemplified by chemokines. , 2005, Annual review of biochemistry.

[57]  S. Groshen,et al.  Increased CXCL8 (IL-8) expression in Multiple Sclerosis , 2004, Journal of Neuroimmunology.

[58]  S. Weis,et al.  Expression of tenascin‐C in various human brain tumors and its relevance for survival in patients with astrocytoma , 2003, Cancer.

[59]  Matthias Chiquet,et al.  Tenascins: regulation and putative functions during pathological stress , 2003, The Journal of pathology.

[60]  Timothy N. C. Wells,et al.  Glycosaminoglycan binding and oligomerization are essential for the in vivo activity of certain chemokines , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[61]  T. Betsuyaku,et al.  Increased levels of interleukin-8 in BAL fluid from smokers susceptible to pulmonary emphysema , 2002, Thorax.

[62]  Shuhei Yamada,et al.  Oversulfated Chondroitin/Dermatan Sulfates Containing GlcAβ1/IdoAα1–3GalNAc(4,6-O-disulfate) Interact with L- and P-selectin and Chemokines* , 2002, The Journal of Biological Chemistry.

[63]  S. Rafii,et al.  Plasma elevation of stromal cell-derived factor-1 induces mobilization of mature and immature hematopoietic progenitor and stem cells. , 2001, Blood.

[64]  P. Jones,et al.  Tenascin-C in development and disease: gene regulation and cell function. , 2000, Matrix biology : journal of the International Society for Matrix Biology.

[65]  M. Chiquet,et al.  Rapid and reciprocal regulation of tenascin-C and tenascin-Y expression by loading of skeletal muscle. , 2000, Journal of cell science.

[66]  Jennifer R. Harrington,et al.  The Role of MCP‐1 in Atherosclerosis , 2000, Stem cells.

[67]  C. Caux,et al.  Regulation of dendritic cell trafficking: a process that involves the participation of selective chemokines , 1999, Journal of leukocyte biology.

[68]  D. Spillmann,et al.  Defining the Interleukin-8-binding Domain of Heparan Sulfate* , 1998, The Journal of Biological Chemistry.

[69]  H. Augustin,et al.  Endothelial cells differentially express functional CXC-chemokine receptor-4 (CXCR-4/fusin) under the control of autocrine activity and exogenous cytokines. , 1998, Biochemical and biophysical research communications.

[70]  M. Baggiolini Chemokines and leukocyte traffic , 1998, Nature.

[71]  R. Terkeltaub,et al.  A leukocyte homologue of the IL-8 receptor CXCR-2 mediates the accumulation of macrophages in atherosclerotic lesions of LDL receptor-deficient mice. , 1998, The Journal of clinical investigation.

[72]  M. Baggiolini,et al.  Eotaxin-2, a Novel CC Chemokine that Is Selective for the Chemokine Receptor CCR3, and Acts Like Eotaxin on Human Eosinophil and Basophil Leukocytes , 1997, The Journal of experimental medicine.

[73]  H. Erickson,et al.  Glycosaminoglycans modulate fibronectin matrix assembly and are essential for matrix incorporation of tenascin-C. , 1997, Journal of cell science.

[74]  T. Springer,et al.  A highly efficacious lymphocyte chemoattractant, stromal cell-derived factor 1 (SDF-1) , 1996, The Journal of experimental medicine.

[75]  H. Kondo,et al.  Expression of the chemokine superfamily in rheumatoid arthritis , 1994, Clinical and experimental immunology.

[76]  J. Hsuan,et al.  Eotaxin: a potent eosinophil chemoattractant cytokine detected in a guinea pig model of allergic airways inflammation , 1994, The Journal of experimental medicine.

[77]  E. Mackie,et al.  Expression of tenascin by vascular smooth muscle cells. Alterations in hypertensive rats and stimulation by angiotensin II. , 1992, The American journal of pathology.

[78]  Y. Kawarada,et al.  Tenascin is a stromal marker for epithelial malignancy in the mammary gland. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[79]  Carlos A V Barreto,et al.  Prediction and targeting of GPCR oligomer interfaces. , 2020, Progress in molecular biology and translational science.

[80]  I. Udalova,et al.  Expression and immune function of tenascin-C. , 2011, Critical reviews in immunology.

[81]  B. Kamenov,et al.  Serum and synovial fluid concentrations of CCL2 (MCP-1) chemokine in patients suffering rheumatoid arthritis and osteoarthritis reflect disease activity. , 2009, Bratislavske lekarske listy.

[82]  J. Couchman,et al.  Syndecans as receptors and organizers of the extracellular matrix , 2009, Cell and Tissue Research.

[83]  Masashi Suzuki,et al.  Glycosaminoglycan affinity of the complete fibroblast growth factor family. , 2009, Biochimica et biophysica acta.

[84]  K. Midwood,et al.  J. Cell Commun. Signal. (2009) 3:287–310 DOI 10.1007/s12079-009-0075-1 RESEARCH ARTICLE The role of tenascin-C in tissue injury and tumorigenesis , 2009 .

[85]  P. Proost,et al.  The role of chemokines in inflammation , 1996, International journal of clinical & laboratory research.

[86]  W. C. Johnson,et al.  Structural information on proteins from circular dichroism spectroscopy possibilities and limitations. , 1995, Pharmaceutical biotechnology.